[
  {
    "ts": null,
    "headline": "Abbott (ABT) Outperforms Broader Market: What You Need to Know",
    "summary": "In the latest trading session, Abbott (ABT) closed at $132.65, marking a +1.4% move from the previous day.",
    "url": "https://finnhub.io/api/news?id=e1ffb5c8f4d60ababc363d4d9f1e9e766a3ed8045ed97582a3fe7cd4f7eac344",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743458414,
      "headline": "Abbott (ABT) Outperforms Broader Market: What You Need to Know",
      "id": 133632985,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "In the latest trading session, Abbott (ABT) closed at $132.65, marking a +1.4% move from the previous day.",
      "url": "https://finnhub.io/api/news?id=e1ffb5c8f4d60ababc363d4d9f1e9e766a3ed8045ed97582a3fe7cd4f7eac344"
    }
  },
  {
    "ts": null,
    "headline": "Abbott Laboratories stock outperforms competitors on strong trading day",
    "summary": "Abbott Laboratories stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=267e01d01b0bb099891a28b484824ae0318973abb09a1d47c9c61261ddd6ffad",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743438720,
      "headline": "Abbott Laboratories stock outperforms competitors on strong trading day",
      "id": 133636631,
      "image": "",
      "related": "ABT",
      "source": "MarketWatch",
      "summary": "Abbott Laboratories stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=267e01d01b0bb099891a28b484824ae0318973abb09a1d47c9c61261ddd6ffad"
    }
  },
  {
    "ts": null,
    "headline": "Best Dividend Aristocrats For April 2025",
    "summary": "Dividend Aristocrats in 2025 show resilience, outperforming the S&P 500. Click here to read what investors need to know.",
    "url": "https://finnhub.io/api/news?id=8d2f7e6be3053b554cc8ee87405abf96ff95f26b38f72e7f7cdf82cef0d639bd",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743437243,
      "headline": "Best Dividend Aristocrats For April 2025",
      "id": 133629387,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2165465384/image_2165465384.jpg?io=getty-c-w1536",
      "related": "ABT",
      "source": "SeekingAlpha",
      "summary": "Dividend Aristocrats in 2025 show resilience, outperforming the S&P 500. Click here to read what investors need to know.",
      "url": "https://finnhub.io/api/news?id=8d2f7e6be3053b554cc8ee87405abf96ff95f26b38f72e7f7cdf82cef0d639bd"
    }
  },
  {
    "ts": null,
    "headline": "GE HealthCare's Latest Product Launch to Boost Cardiology Care",
    "summary": "GEHC's latest commercial launch of Flyrcado and the grant of pass-through status by CMS aim to serve a wider patient pool across the United States.",
    "url": "https://finnhub.io/api/news?id=81f3a3e72edf57bcd70a741b0699bd7fb3e190093b2aecbb94a3bc7c7c889162",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743428700,
      "headline": "GE HealthCare's Latest Product Launch to Boost Cardiology Care",
      "id": 133627816,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "GEHC's latest commercial launch of Flyrcado and the grant of pass-through status by CMS aim to serve a wider patient pool across the United States.",
      "url": "https://finnhub.io/api/news?id=81f3a3e72edf57bcd70a741b0699bd7fb3e190093b2aecbb94a3bc7c7c889162"
    }
  },
  {
    "ts": null,
    "headline": "The Zacks Analyst Blog Highlights McDonald's, Abbott Laboratories, O'Reilly Automotive and MIND Technology",
    "summary": "McDonald's, Abbott Laboratories, O'Reilly Automotive and MIND Technology are part of the Zacks top Analyst Blog.",
    "url": "https://finnhub.io/api/news?id=76f0735f940c7fe004d9e7cb6b14c4e6cd649e4085472df7c4015121358662c9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743427140,
      "headline": "The Zacks Analyst Blog Highlights McDonald's, Abbott Laboratories, O'Reilly Automotive and MIND Technology",
      "id": 133627817,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "McDonald's, Abbott Laboratories, O'Reilly Automotive and MIND Technology are part of the Zacks top Analyst Blog.",
      "url": "https://finnhub.io/api/news?id=76f0735f940c7fe004d9e7cb6b14c4e6cd649e4085472df7c4015121358662c9"
    }
  },
  {
    "ts": null,
    "headline": "New Late-Breaking Data Reinforce Benefits of Abbott's TriClip™ for People With Leaky Tricuspid Heart Valve",
    "summary": "Abbott (NYSE: ABT) today announced late-breaking data from its TRILUMINATE™ Pivotal trial that show the TriClip™ transcatheter edge-to-edge repair (TEER) system to treat tricuspid regurgitation (TR), or a leaky heart valve, offers substantial and sustained improvements in the severity of TR after two years. The results also demonstrate the TriClip device significantly reduced the rate of hospitalizations due to heart failure compared to medical therapy, while offering long-term quality-of-life b",
    "url": "https://finnhub.io/api/news?id=f51c139e422ada8246706021307a84fa6b64a8cb9c53ed2c258cb82aa6d2084b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743426000,
      "headline": "New Late-Breaking Data Reinforce Benefits of Abbott's TriClip™ for People With Leaky Tricuspid Heart Valve",
      "id": 133627818,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Abbott (NYSE: ABT) today announced late-breaking data from its TRILUMINATE™ Pivotal trial that show the TriClip™ transcatheter edge-to-edge repair (TEER) system to treat tricuspid regurgitation (TR), or a leaky heart valve, offers substantial and sustained improvements in the severity of TR after two years. The results also demonstrate the TriClip device significantly reduced the rate of hospitalizations due to heart failure compared to medical therapy, while offering long-term quality-of-life b",
      "url": "https://finnhub.io/api/news?id=f51c139e422ada8246706021307a84fa6b64a8cb9c53ed2c258cb82aa6d2084b"
    }
  }
]